Royal Bank of Canada’s Jazz Pharmaceuticals JAZZ Stock Holding History

Royal Bank of Canada’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,000	Closed	-$1.49M	–	6840
2019 Q4	$1.49M	Buy	+10,000	New	+$1.36M	﹤0.01%	3122
2017 Q1	–	Sell	-2,000	Closed	-$218K	–	6713
2016 Q4	$218K	Hold	2,000	–	–	﹤0.01%	4422
2016 Q3	$243K	Hold	2,000	–	–	﹤0.01%	4289
2016 Q2	$283K	Buy	+2,000	New	+$295K	﹤0.01%	4150
2016 Q1	–	Sell	-30,000	Closed	-$4.22M	–	6504
2015 Q4	$4.22M	Buy	+30,000	New	+$4.16M	﹤0.01%	1972

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Royal Bank of Canada's JAZZ Position: Q1 2026 in Review

Royal Bank of Canada increased its Jazz Pharmaceuticals (JAZZ) stake by 17% in Q1 2026, buying an estimated $1.17M and bringing the position to 45,251 shares worth $8.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2022.

Royal Bank of Canada first reported a position in JAZZ in Q2 2013 and has held it in 52 quarters since. The position peaked at $69.2M in Q4 2016. 573 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Royal Bank of Canada held 45,251 shares of Jazz Pharmaceuticals worth $8.56M as of Q1 2026.
Royal Bank of Canada bought 6,695 Jazz Pharmaceuticals shares in Q1 2026, an estimated $1.17M.
Jazz Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #2022 holding.
Royal Bank of Canada first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Royal Bank of Canada's Jazz Pharmaceuticals position peaked at $69.2M in Q4 2016.
573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.